3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Multiple Myeloma
9
Recurrence
5
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Triple Negative Breast Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumor Malignancy
1
Smooth Muscle Tumor
1
Sarcoma, Clear Cell
1
Recurrent Squamous Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
selinexor
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled